← Leaderboards
Bradley T Christian
University Of Wisconsin-Madison
$32,543,306
Attributed
$50,740,332
Total exposure
7
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $29.6M · FY2008–25$50M$37.5M$25M$12.5M$0
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$153,239,067 · 8
By mechanism
U19$123,555,896 · 2
U01$20,351,851 · 1
R01$5,288,870 · 1
RF1$2,206,425 · 1
S10$1,286,910 · 1
R21$400,615 · 1
Top collaborators
- Benjamin L Handen21 shared
- William E Klunk11 shared
- Elizabeth Head10 shared
- Mark Mapstone10 shared
- Barbara Brigitta Bendlin6 shared
- Sterling C Johnson6 shared
- Jogesh Mukherjee2 shared
Most similar at University Of Wisconsin-Madison
Same institution · by research overlap
- Richard J Davidson$53,083,653
- Barbara Brigitta Bendlin$36,811,854
- Brian William Pogue$26,364,458
- Reid Spencer Alisch$3,126,578
- Kirk J Hogan$1,729,948
Others in their field
Top investigators on “Alzheimer&Apos”
- Jose A Luchsinger · Columbia University Health Sciences$56,595,040
- Eric M Reiman · Banner Health$48,982,487
- Yadong Huang · J. David Gladstone Institutes$40,311,515
- Lindsay A. Farrer · Boston University Medical Campus$34,189,802
- David M Holtzman · Washington University$28,985,806
- Michael W Weiner · Northern California Institute Res &Educ$28,197,224
Research focus
Alzheimer&AposS DiseaseBiological MarkersImageNerve DegenerationCohortDementiaAmyloidResearch PersonnelTau ProteinsPositron-Emission TomographyBrainNeuropathologyGeneral PopulationParticipantAdultDown SyndromeSenile PlaquesProtocols DocumentationCognitiveCommunitiesPreventClinical TrialsAlzheimerâS Disease Biomarker
Grant awards (39)
Alzheimer Biomarker Consortium - Down Syndrome (ABC-DS)$17,980,649
U19 · FY2025 · AG
Core D: Neuroimaging Core$3,730,783
U19 · FY2025 · AG · contact PI
Alzheimer Biomarker Consortium - Down Syndrome (ABC-DS)$404,804
U19 · FY2025 · AG
Alzheimer Biomarker Consortium - Down Syndrome (ABC-DS)$21,776,522
U19 · FY2023 · AG
Core D: Neuroimaging Core$6,650,768
U19 · FY2023 · AG · contact PI
Alzheimer Biomarker Consortium - Down Syndrome (ABC-DS) - KUMC Field Site Supplement$774,896
U19 · FY2023 · AG
Alzheimer Biomarker Consortium - Down Syndrome (ABC-DS) - Supplement$438,809
U19 · FY2023 · AG
Alzheimer Biomarker Consortium - Down Syndrome (ABC-DS)$19,233,560
U19 · FY2022 · AG
Core D: Neuroimaging Core$4,326,517
U19 · FY2022 · AG · contact PI
SV2A PET imaging in Alzheimer's Disease$1,129,244
R01 · FY2022 · AG
ABC-DS MOMsâ Supplement (Modification of Maternal AD risk in DS)$788,668
U19 · FY2022 · AG
Alzheimer Biomarker Consortium - Down Syndrome (ABC-DS)-04 Supplement 5$765,262
U19 · FY2022 · AG
Alzheimer Biomarker Consortium - Down Syndrome (ABC-DS)$19,355,148
U19 · FY2021 · AG
Core D: Neuroimaging Core$4,251,051
U19 · FY2021 · AG · contact PI
SV2A PET imaging in Alzheimer's Disease$1,131,446
R01 · FY2021 · AG
Alzheimer Biomarker Consortium - Down Syndrome (ABC-DS)$20,980,417
U19 · FY2020 · AG
Core D: Neuroimaging Core$2,098,042
U19 · FY2020 · AG · contact PI
SV2A PET imaging in Alzheimer's Disease$1,133,380
R01 · FY2020 · AG
PET Imaging agents for a4b2 Nicotinic Receptors$249,088
RF1 · FY2020 · AG
Neurodegeneration in Aging Down Syndrome (NiAD): A Longitudinal Study of Cognition and Biomarkers of Alzheimer's Disease$4,277,120
U01 · FY2019 · AG
PET Imaging agents for a4b2 Nicotinic Receptors$1,957,337
RF1 · FY2019 · AG
SV2A PET imaging in Alzheimer's Disease$755,504
R01 · FY2019 · AG
Neurodegeneration in Aging Down Syndrome (NiAD): A Longitudinal Study of Cognition and Biomarkers of Alzheimer's Disease$586,856
U01 · FY2019 · AG
SV2A PET imaging in Alzheimer's Disease$380,731
R01 · FY2019 · AG
Neurodegeneration in Aging Down Syndrome (NiAD): A Longitudinal Study of Cognition and Biomarkers of Alzheimer's Disease$3,742,475
U01 · FY2018 · AG
Biograph Horizon PET/CT$1,286,910
S10 · FY2018 · OD · contact PI
SV2A PET imaging in Alzheimer's Disease$758,565
R01 · FY2018 · AG
Neurodegeneration in Aging Down Syndrome (NiAD): A Longitudinal Study of Cognition and Biomarkers of Alzheimer's Disease$386,628
U01 · FY2018 · AG
Neurodegeneration in Aging Down Syndrome (NiAD): A Longitudinal Study of Cognition and Biomarkers of Alzheimer's Disease$129,573
U01 · FY2018 · AG
Neurodegeneration in Aging Down Syndrome (NiAD): A Longitudinal Study of Cognition and Biomarkers of Alzheimer's Disease$69,940
U01 · FY2018 · AG
Neurodegeneration in Aging Down Syndrome (NiAD): A Longitudinal Study of Cognition and Biomarkers of Alzheimer's Disease$3,623,562
U01 · FY2017 · AG
Neurodegeneration in Aging Down Syndrome (NiAD): A Longitudinal Study of Cognition and Biomarkers of Alzheimer's Disease$163,334
U01 · FY2017 · AG
Neurodegeneration in Aging Down Syndrome (NiAD): A Longitudinal Study of Cognition and Biomarkers of Alzheimer's Disease$158,939
U01 · FY2017 · AG
Neurodegeneration in Aging Down Syndrome (NiAD): A Longitudinal Study of Cognition and Biomarkers of Alzheimer's Disease$3,556,865
U01 · FY2016 · AG
Neurodegeneration in Aging Down Syndrome (NiAD): A Longitudinal Study of Cognition and Biomarkers of Alzheimer's Disease$3,656,559
U01 · FY2015 · AG
[F-18]Mefway PET to measure 5-HT1A receptors in gene x environment interactions$218,870
R21 · FY2010 · MH · contact PI
[F-18]Mefway PET to measure 5-HT1A receptors in gene x environment interactions$181,745
R21 · FY2009 · MH · contact PI
A novel PET radiotracer to study 5HT-1A receptors in fetal alcohol exposure$74,250
R03 · FY2009 · AA · contact PI
A novel PET radiotracer to study 5HT-1A receptors in fetal alcohol exposure$74,250
R03 · FY2008 · AA · contact PI